India's quiet infertility surge: rising PCOS, costly IVF, no insurance cover

Infertility in India is shifting from a private family matter into a measurable, costly public-health problem — one that the country's health system is structurally underprepared to absorb. A 2026 systematic review and meta-analysis of 34 studies published between 1997 and 2023, hosted on the National Library of Medicine's PMC, pooled the data and placed overall infertility prevalence among Indian women aged 15-49 at 8% (95% CI 0.01-0.14), with 5% primary infertility (95% CI 0.03-0.06) and 2% secondary infertility (95% CI 0.01-0.04).

Under a stricter operational definition — currently married women in union for at least five years with no conception — the National Family Health Survey-5 (NFHS-5, 2019-21) records 18.7 per 1,000 women, equivalent to roughly 1.87% at the population scale. Industry data cited by Nova IVF Fertility CEO Shobhit Agarwal via The Hindu puts the colloquial figure at 'one in six couples in India suffer from infertility issues' when male and female factors are pooled.

All three numbers describe a real and growing burden. Newsorga's analysis: the question is no longer whether clinical infertility is rising among Indian women — the data is clear that it is — but why, what it costs, and why the public-health system has not caught up.

What 'infertility' means here

Clinicians use a specific definition. The WHO and Indian Society of Assisted Reproduction (ISAR) define infertility as the inability to conceive after 12 months of regular unprotected intercourse (or 6 months for women aged 35 and older). Primary infertility describes couples who have never conceived; secondary infertility describes couples who have conceived previously but cannot do so again.

Two further distinctions matter for the Indian picture, per the ICMR-NIRRCH study released in December 2025 via The Hindu:

• Female factor contributes to 46% of Indian infertility cases.
• Male factor contributes to 20%.
• Both partners contribute in 10% of cases.
• The remainder are idiopathic (unexplained) or multi-factorial.

So while this piece focuses on the female experience — which is where social pressure, clinical observation and policy debate are most concentrated — the underlying biology is split roughly two-thirds female, one-third male.

Why clinicians say it is rising

Times of India reported in 2025 that gynaecologists across Delhi's public and private tertiary centres are observing a clear downward shift in age-of-onset. Dr Juhi Bharti, Additional Professor at the Department of Obstetrics and Gynaecology at AIIMS Delhi: "Clinically, we are now observing diminished ovarian reserve in women in their late 20s, a trend that was previously more common in the late 30s. While not necessarily irreversible, this shift highlights the need for early awareness and timely intervention."

Dr Priti Arora Dhamija, senior consultant and lead IVF at Sitaram Bhartia Institute: "There is a clear and concerning shift in women's health today, where issues related to hormonal imbalance and fertility are appearing much earlier than we traditionally observed... One of the key reasons is the earlier onset of puberty with many girls now attaining menarche as early as 8-9 years, which can lead to a relatively earlier decline in ovarian reserve."

The clinically-supported drivers, drawn from the 2026 PMC review, ToI's clinician interviews, and the New Indian Express clinical-practice interview:

1. PCOS at population scale. Polycystic Ovary Syndrome is the leading cause of ovulatory dysfunction in Indian women, and ovulatory dysfunction is the leading cause of female infertility. Prevalence estimates from ISAR and peer-reviewed epidemiology cited by ToI place PCOS at 10-17.4% of reproductive-age women in India, with the higher end of that band concentrated in urban populations. The clinicians ToI interviewed described PCOS as affecting "nearly one in five women of reproductive age in India."

2. Delayed motherhood. Average age at first childbirth has risen in metros — driven by longer education, later marriage, career trajectories and housing economics — and ovarian reserve declines steeply through the 30s. Indian women postponing first conception to 32-35 now face the same biological clock that European and US women have been managing for two decades, but with significantly weaker support infrastructure.

3. The lifestyle stack. Urbanisation, sedentary office work, ultra-processed food, sleep disruption, chronic stress, screen exposure and rising obesity rates compound metabolic dysfunction. Dr Bhawani Shekhar at Sir Ganga Ram Hospital flagged the constellation to ToI: "Unhealthy diet, sedentary routine and lack of regular exercise play a significant role, with smoking and alcohol further contributing... chronic stress increases cortisol levels and poor sleep affects the circadian rhythm, further impacting hormone levels and ovarian health."

4. Environmental exposome. The 2026 PMC review and the International Journal of Research in Pharmacy and Allied Science review both highlight elevated PM2.5 fine-particulate pollution (where Indian cities consistently rank among the worst globally), endocrine-disrupting chemicals (EDCs) in food packaging and personal-care products, and microplastics. These factors directly impair ovarian reserve and embryogenesis in the published mechanistic literature.

5. Genital tuberculosis — the hidden epidemic. India still carries the largest tuberculosis burden in the world, and genital TB is a chronic, frequently silent cause of tubal-factor infertility in women — particularly in rural and lower-income populations where diagnosis is often delayed. It does not get the policy attention it warrants because it sits at the intersection of two stigmatised conditions (TB and infertility).

6. Earlier puberty. Dr Dhamija's observation on menarche at 8-9 years is consistent with published Lancet Child and Adolescent Health data showing a multi-decade decline in age at menarche globally, linked to nutrition transitions, rising childhood obesity and environmental exposures. Earlier menarche extends total reproductive years on paper but in practice front-loads ovarian use.

The cost wall: ₹1 lakh per IVF cycle

The single most important policy data point in this story is the ICMR-NIRRCH cost study released via The Hindu in December 2025, undertaken at the request of the Ministry of Health and Family Welfare to assess IVF's inclusion in Pradhan Mantri Jan Arogya Yojana (PM-JAY), the government's flagship public health insurance scheme.

Key findings (Indian Council of Medical Research-National Institute for Research in Reproductive and Child Health, sample: 30 IVF patients + 100 general infertility patients across 3 public and 2 private tertiary facilities):

• Average out-of-pocket spending on a single IVF cycle: > ₹1,00,000 in both private and public hospitals. The price gap most patients expect between government hospitals and private clinics is substantially smaller than expected once medicines, diagnostics, and ancillary costs are counted.
• Median out-of-pocket spending on general infertility treatment (non-IVF): ₹11,317 per cycle.
• Health-system cost of one year of infertility management in public facilities: between ₹6,822 and ₹11,075.
• Medical costs of one ART cycle are 166.4% of the patient's average annual income in India (systematic-review evidence from low- and middle-income countries cited by The Hindu).
• Only 8% of infertile couples in the study required advanced ART such as IVF; the rest could be managed with ovulation induction, intrauterine insemination (IUI), or surgical interventions.
• Roughly 3 stimulated IVF cycles are typically required for "a good chance of success" per the clinicians the study consulted — meaning the realistic financial commitment for an Indian couple committed to IVF is closer to ₹3-5 lakh, before any travel, accommodation or lost-income costs.

Newsorga's read: that ₹3-5 lakh effective commitment is a year's median household income for most working-class urban families and multiple years' income for tier-2 and tier-3 households. It is a transparent and well-documented affordability wall.

The regulatory gap

India has a regulatory framework for assisted reproductive technology — the Assisted Reproductive Technology (Regulation) Act, 2021 and the ART Rules notified under it — which governs egg and sperm donation, cryopreservation, clinic registration, and quality criteria. But, per The Hindu's reading of the ICMR-NIRRCH report:

• The Act does not regulate prices. ART clinics in the private sector — which provide the vast majority of fertility services because public ART centres are vanishingly few — set their own rates.
• Public ART capacity is small. Independent published estimates put the number of public ART clinics in India at about 10 nationally as of 2019, and growth since has been incremental.
• PM-JAY does not currently cover fertility treatment. It explicitly excludes fertility care from its package, while covering most secondary and tertiary care otherwise.
• CGHS (Central Government Health Scheme) reimburses a one-time amount of ₹65,000 or actual cost, whichever is lower, for three fresh IVF cycles — but only for government employees and dependents meeting specific eligibility criteria.
• The Health Technology Assessment in India (HTAIn) under the Department of Health Research (DHR) has now formally recommended PM-JAY include IVF at ₹81,332 per cycle.

That ₹81,332 figure is the closest thing the country has to an official price-anchor for IVF, and the HTA report also flags that outpatient (OPD) expenses — which account for the majority of infertility treatment costs — are not covered under PM-JAY and would need a structural inclusion change rather than a simple rate addition.

State-level disparities

The NFHS-5 (2019-21) state-level data, as analysed in the Journal of Reproduction & Infertility, shows the burden is not evenly distributed. States with the highest prevalence include Goa, Lakshadweep, Chhattisgarh, Sikkim and Kerala. Newsorga's structural read:

• High-prevalence states correlate with a combination of later average age at marriage (Kerala, Goa), high environmental exposure or industrial profile (Chhattisgarh), and small-population reporting effects (Lakshadweep, Sikkim).
• Low-prevalence states are not necessarily 'healthier' on this metric — they often reflect under-diagnosis driven by stigma, limited tertiary-care access, and surveys that miss women who never present clinically. Bihar, Uttar Pradesh, Madhya Pradesh and Jharkhand carry well-documented under-reporting on women's reproductive health metrics generally.

Why the social cost is higher than the clinical number suggests

Even at the NFHS-5 figure of 18.7 per 1,000 married women — the conservative number — the social weight of infertility in India is multiplied by three structural amplifiers:

1. Marital and family pressure. Childbearing is socially expected within the first two to three years of marriage in most communities. A woman in India experiencing primary infertility frequently absorbs blame at the household and extended-family level regardless of the underlying biology — recall that 20% of the cause is male-factor and 46% female-factor.

2. Mental-health load. The ICMR-NIRRCH study explicitly identified "pain/discomfort and anxiety/depression" as the largest contributors to poor health-related quality of life among infertility patients, with uterine-factor infertility and endometriosis patients reporting the worst quality-of-life outcomes. Mental-health services are themselves underdeveloped in most of India's public health system.

3. Employment-and-leave implications. Indian labour law does not currently mandate IVF leave or fertility-treatment accommodation. Women undergoing multiple stimulated cycles routinely use annual leave or unpaid leave to manage clinic visits, injections and recovery, which compounds the income-loss component of the 166.4% annual-income cost figure.

Three things to watch over the next 12 months

1. PM-JAY inclusion. The HTA recommendation of ₹81,332/cycle is on the Ministry of Health and Family Welfare's desk. Newsorga will track whether the FY 2026-27 budget cycle moves it from recommendation to operational scheme — the political win for the government would be substantial, but the fiscal envelope is meaningful at population scale.

2. ART price regulation. Industry pushback against price ceilings is strong; women's-health advocacy groups and NCW-linked petitions are pushing for upper limits. Whether the ART Act amendments include price controls will be a politically charged debate in the next parliamentary session.

3. Workplace policy. Companies in the IT and BFSI sectors — where the affected cohort is concentrated — are quietly adding IVF coverage to corporate health-insurance plans in 2025-2026. Newsorga's view: this is the path of least resistance, and it will further widen the gap between metropolitan formal-sector access and rural/informal-sector access.

Bottom line. India has the world's largest population of reproductive-age women, a meta-analysis-confirmed 8% infertility prevalence in that cohort, clinicians documenting earlier age-of-onset, a regulatory framework that does not control prices, and a flagship health-insurance scheme that excludes fertility care. The numbers are out. The question now is policy translation. Newsorga will follow the PM-JAY decision and the ART Act amendment debate as they progress.